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Abstract
Background: The discovery of myositis-specific autoantibodies and myositis-associated autoantibodies has led to a
new serological classification. Human U3 RNP, which consists of the U3 small nucleolar RNA and anti-U3 RNP antibody,
is directed against one of the subunits. Anti-U3 RNP antibodies have been detected in 5–8 % of patients with systemic
sclerosis, and antibody-positive patients with systemic sclerosis have shown more frequent skeletal muscle involvement
than that of antibody-negative patients with systemic sclerosis.
Case presentation: A 74-year-old Japanese man positive for anti-U3 RNP antibody was referred to our hospital
because of gait disturbance and dysphagia. His serum myoglobin and creatine kinase levels were elevated, and
myopathic changes were observed in his proximal legs by needle electromyography. A muscle biopsy was performed
at the quadriceps femoris muscle, which showed high signal intensity on fat-suppressed and T2-weighted magnetic
resonance images. The patient was diagnosed with probable polymyositis because CD8-positive lymphocytes had
invaded only the endomysium and not into the muscle fibers. Severe proliferation of the interstitial connective tissue
and edematous changes were observed. Oral prednisolone therapy was started, and the patient’s muscle weakness of
the proximal limbs improved remarkably within 1 month. Dysphagia caused by incomplete function of the
cricopharyngeal muscle persisted for 5 years.
Conclusions: Our findings indicate that mild muscle weakness with steroid-resistant dysphagia may be a clinical
feature of patients with anti-U3 RNP antibody-positive inflammatory myopathy.
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Background
The inflammatory myopathies are classified into three
major subsets (dermatomyositis, polymyositis, and inclu-
sion body myositis) based on clinical, histopathological,
immunological, and demographic criteria. The discovery of
myositis-specific and myositis-associated autoantibodies
has led to a new serological classification. Human U3 RNP
consists of the U3 small nucleolar RNA and at least six pro-
tein subunits. One of the subunits, fibrillarin, is a 34 kDa
basic protein and is considered to be the main antigenic
determinant. The presence of anti-U3 RNP (antifibrillarin)
antibodies is highly specific to systemic sclerosis (SSc) and
is associated with skeletal muscle disease [1,2]. Here, we
report a case of a patient with anti-U3 RNP antibody
positivity who showed the symptoms of inflammatory
myopathy, but not those of SSc.
Case presentation
A 74-year-old Japanese man was referred to our hospital
for gait disturbance and dysphagia. He had been diagnosed
with prostate cancer (T2bN0M0) at 70 years old and had
been treated by linear accelerator (70 Gy), followed by
endocrine therapy. He had had a slightly elevated creatine
kinase (CK) level (464 IU/L) in a medical examination
when he was 72 years old, but he remained asymptomatic.
The patient had noticed difficulty in standing up from a
chair and swallowing solid foods 18 months before referral
to our hospital. He had a high tendency to fall and had no-
ticed difficulty in climbing the stairs starting from 6 months
before referral to our hospital.
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Condition at initial presentation
The patient’s blood pressure was 132/66 mmHg, his
pulse rate was 66 beats/minute and regular, his body
temperature was 36.7 °C, and his weight was 49 kg (with
a 6-kg weight loss in the past year). His heart and breath
sounds were normal. No skin sclerosis or Raynaud’s
phenomenon was observed. His higher cerebral function
revealed that he was alert and well-oriented. His mental
status was normal, and his cranial nervous system ap-
peared to be intact. Muscle atrophy was noted in the
proximal parts of his upper and lower extremities, and
manual muscle testing showed decreases to level 4 in his
proximal upper limbs and level 3 in his proximal lower
limbs. His muscle tone and deep tendon reflexes were
within normal ranges. No abnormal findings were ob-
served in his sensory, cerebellar, and autonomic nervous
systems.
Laboratory findings
The patient’s hematology examination revealed no ab-
normal findings. His serum CK, aspartate aminotransfer-
ase, alanine aminotransferase, aldolase, and myoglobin
levels were elevated. His KL-6 level was within normal
limits (212 U/L). All of his tumor markers were negative.
As for his autoimmune systems, his serum antinuclear
antibody (5120-fold) titer was elevated, but his other
autoantibodies were negative. Only his anti-U3 RNP
antibodies were positive; his myositis-specific autoanti-
bodies and myositis-associated autoantibodies were
negative (Table 1). For assessment, a commercially avail-
able line blot test kit (Myositis and Systemic Sclerosis
Profile Euroline Blot test kit; Euroimmun, Lübeck,
Germany) was used according to the manufacturer’s
protocols.
The patient’s electrocardiogram showed no remark-
able findings. Upper gastrointestinal tract endoscopy
showed no abnormalities such as reflux esophagitis. A
computed tomographic scan showed no interstitial
pneumonic or malignant findings. Needle electromyog-
raphy of the patient’s proximal legs demonstrated
myopathic changes without denervation potentials. T2-
weighted and short tau inversion recovery magnetic
resonance imaging scans revealed high signal intensity
in both the flexors and extensors of the thigh muscles
(Fig. 1a). Videofluoroscopic examination of the patient’s
swallowing showed poor tongue movements in the oral
stage and impaired opening of the esophageal muscle,
as well as a cricopharyngeal bar on the posterior
pharyngeal wall in the pharyngeal stage (Fig. 1b). In the
esophageal stage, no obstruction, retention of the
contrast material in the lower esophagus, or impaired
opening of the lower esophageal sphincter were
observed. Muscle biopsy specimens from the patient’s
Table 1 Laboratory data
Test Value
Hematology
White blood cells 5700/μl
Red blood cells 441 × 104/μl
Hemoglobin 13.7 g/dl
Platelet count 18.9 × 104/μl
Chemistry































CK creatine kinase, AST aspartate aminotransferase, ALT alanine aminotransferase,
MPO-ANCA myeloperoxidase antineutrophil cytoplasmic antibody, PR3-ANCA
proteinase 3 antineutrophil cytoplasmic antibody, SRP signal recognition particle,
dsDNA double-stranded DNA, ssDNA single-stranded DNA, RF rheumatoid factor,
CCP cyclic citrullinated peptide, Scl-70 DNA topoisomerase I, Jo-1 hystidyl-tRNA
synthetase, PL7 threonyl-tRNA synthetase, PL12 alanyl-tRNA synthetase, EJ
glycyl-tRNA synthetase, OJ isoleucyl-tRNA synthetase,
U1 RNP U1-ribonucleoprotein, U3 RNP anti-U3-ribonucleoprotein
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quadriceps femoris muscle showed round muscle fibers
of various sizes, marked proliferation of connective
tissue, and edematous changes. No perifascicular atro-
phy was observed. The main inflammatory cells invad-
ing the endomysium were CD8-positive T lymphocytes
surrounding major histocompatibility complex (MHC)
class I-positive, non-necrotic muscle fibers. No lympho-
cyte invasion into the muscle fibers or deposition of
complement along the vascular wall was observed
(Fig. 2).
Course
Oral prednisolone (1 mg/kg/day) therapy was started, and
the patient’s muscle strength of upper and lower extremities
normalized within 1 month, along with his serum CK, al-
dolase, and myoglobin levels. Although a videofluoroscopic
swallowing examination showed improvement of tongue
movements during the oral stage, impaired function of the
cricopharyngeal muscle and presence of the cricopharyn-
geal bar persisted. The patient has been followed on a regi-
men of prednisolone 5 mg/day for 5 years, and no relapse
of the muscle weakness has been observed, except for
dysphagia.
Discussion
We present a case of a 74-year-old man who had mild
proximal muscle weakness, as well as dysphagia due to
incomplete opening of the cricopharyngeal muscle. In this
patient, laboratory data showed elevated serum levels of
CK, myoglobin, and aldolase while myopathic changes in
the proximal legs were observed by needle electromyog-
raphy. Although CD8-positive T lymphocytes were sur-
rounding the MHC-1-positive, non-necrotic muscle fibers,
no lymphocyte invasion into the muscle fibers was ob-
served. On the basis of these clinical features, we diagnosed
our patient as having probable polymyositis [3,4].
This patient showed the presence of anti-U3 RNP anti-
bodies but did not fulfill the other diagnostic criteria for
SSc [5]. Koenig et al. reported heterogeneity of autoanti-
bodies in 100 patients with autoimmune myositis. Fourteen
patients (14 %) were positive for anti-U3 RNP antibodies.
All except one of these patients (93 %) had other autoanti-
bodies, including anti-Ku, anti-Ro, and anti-Jo-1 antibodies
[6]. Raynaud’s phenomenon and lung involvement are asso-
ciated with anti-U3 RNP antibody-positive myositis. Thus,
patients with myositis who are anti-U3 RNP-positive usu-
ally show overlap syndrome. Therefore, patients with only
myositis who are positive for anti-U3 RNP antibody alone
are extremely rare.
Oh et al. conducted a retrospective review of medical
records of 783 patients with inflammatory myopathy
and found that 13 patients had dysphagia as the initial
presenting symptom (11 patients with inclusion body
myositis, 1 patient with polymyositis, and 1 patient with
overlap syndrome) [7]. Dysphagia is serious and at times
problematic for patients with inflammatory myopathy.
Videofluoroscopic swallowing examination of our pa-
tient revealed a cricopharyngeal bar, which represents
impaired opening of the cricopharyngeal muscle [8].
Dysphagia was an initial symptom in our patient. After
the initiation of oral steroid therapy (40 mg/day), his
serum CK normalized rapidly and his muscle strength
recovered within 1 month. Currently, the patient is being
followed on a regimen of prednisolone 5 mg/day, and no
relapse of his muscle weakness has been observed, except
Fig 1 a Magnetic resonance imaging findings in the femoral muscles.
T2-weighted and short tau inversion recovery magnetic resonance
imaging scans show high signal intensity in both the flexors and
extensors of the thigh muscles. b Videofluoroscopic study using paste
barium. Pharyngeal muscle propulsion (cricopharyngeal bar) was
observed (arrow)
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for dysphagia. Steroid therapy was effective in improving
his muscle weakness, but not his dysphagia. His cricophar-
yngeal muscle damage was more severe than his skeletal
muscle disturbance. Measurement of anti-U3 RNP anti-
bodies has been performed by RNA immunoprecipitation,
which is not a popular technique. Using other methods
such as line immune assay to examine the positivity of the
anti-U3 RNP antibody in inflammatory myopathy is more
feasible.
Conclusions
Our findings indicate that mild muscle weakness with
steroid-resistant dysphagia may be a clinical feature of
patients with only anti-U3 RNP antibody-positive
inflammatory myopathy. Further observational studies are
needed to confirm these findings.
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